Balyasny Asset Management
AMPH icon

Balyasny Asset Management’s Amphastar Pharmaceuticals AMPH Stock Holding History

Balyasny Asset Management’s Portfolio AMPH Stock Details AMPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-77,467
Closed -$2.07M – 2854
2025
Q4 		$2.07M Sell
77,467
-64,385
-45% -$1.66M ﹤0.01% 1840
2025
Q3 		$3.78M Sell
141,852
-124,454
-47% -$3.21M ﹤0.01% 1509
2025
Q2 		$6.11M Buy
266,306
+104,168
+64% +$2.58M 0.01% 1188
2025
Q1 		$4.7M Buy
+162,138
New +$5.18M 0.01% 1278
2023
Q3 		– Sell
-9,144
Closed -$526K – 2226
2023
Q2 		$526K Buy
+9,144
New +$405K ﹤0.01% 1842

Other funds holding AMPH

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $123B AUM 34.51% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $12.2B AUM 12.45% 1-Year Est. Return

Balyasny Asset Management's AMPH Position: Q1 2026 in Review

Balyasny Asset Management sold out of Amphastar Pharmaceuticals (AMPH) in Q1 2026, closing a stake of 77,467 shares — an estimated $2.07M sold.

Balyasny Asset Management first reported a position in AMPH in Q2 2023 and held it in 5 quarters. The position peaked at $6.11M in Q2 2025. 215 funds tracked by Wall St. Rank hold AMPH as of Q1 2026.

  • Balyasny Asset Management reported no remaining Amphastar Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Balyasny Asset Management sold 77,467 Amphastar Pharmaceuticals shares in Q1 2026, an estimated $2.07M.
  • Balyasny Asset Management first reported a position in Amphastar Pharmaceuticals in Q2 2023 and held it in 5 quarters.
  • Balyasny Asset Management's Amphastar Pharmaceuticals position peaked at $6.11M in Q2 2025.
  • 215 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.